Lysosomal Storage Diseases - Global Strategic Business Report

The global market for Lysosomal Storage Diseases was estimated at US$10.4 Billion in 2023 and is projected to reach US$15.2 Billion by 2030, growing at a CAGR of 5.6% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Key Insights:

Market Growth: Understand the significant growth trajectory of the Enzyme Replacement Therapy (ERT) segment, which is expected to reach US$7.3 Billion by 2030 with a CAGR of a 6.1%. The Substrate Reduction Therapy (SRT) segment is also set to grow at 5.3% CAGR for the next 7-year period.
Regional Analysis: Gain insights into the U.S. market, estimated at $3.2 Billion in 2023, and China, forecasted to grow at an impressive 5.3% CAGR to reach $2.6 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

Detailed Market Analysis: Access a thorough analysis of the Global Lysosomal Storage Diseases Market, covering all major geographic regions and market segments.
Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Lysosomal Storage Diseases Market.
Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

How is the Global Lysosomal Storage Diseases Market expected to evolve by 2030?
What are the main drivers and restraints affecting the market?
Which market segments will grow the most over the forecast period?
How will market shares for different regions and segments change by 2030?
Who are the leading players in the market, and what are their prospects?

Report Features:

Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
Company Profiles: Coverage of major players such as Alexion Pharmaceuticals, Inc., BioMarin Pharmaceutical, Inc., Horizon Therapeutics plc, and more.
Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Select Competitors (Total 44 Featured):

Alexion Pharmaceuticals, Inc.
BioMarin Pharmaceutical, Inc.
Horizon Therapeutics plc
Lacerta Therapeutics
Orphazyme ApS
Oxyrane
Sanofi Genzyme
Sanofi SA

I. METHODOLOGYII. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

Influencer Market Insights
World Market Trajectories
Lysosomal Storage Diseases - Global Key Competitors Percentage Market Share in 2024 (E)
Global Economic Update
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)

2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

Table 1: World Recent Past, Current & Future Analysis for Lysosomal Storage Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
Table 2: World Historic Review for Lysosomal Storage Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 3: World 16-Year Perspective for Lysosomal Storage Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
Table 4: World Recent Past, Current & Future Analysis for Enzyme Replacement Therapy (ERT) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
Table 5: World Historic Review for Enzyme Replacement Therapy (ERT) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 6: World 16-Year Perspective for Enzyme Replacement Therapy (ERT) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
Table 7: World Recent Past, Current & Future Analysis for Substrate Reduction Therapy (SRT) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
Table 8: World Historic Review for Substrate Reduction Therapy (SRT) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 9: World 16-Year Perspective for Substrate Reduction Therapy (SRT) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
Table 10: World Recent Past, Current & Future Analysis for Cystine Depleting Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
Table 11: World Historic Review for Cystine Depleting Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 12: World 16-Year Perspective for Cystine Depleting Agents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
Table 13: World Lysosomal Storage Diseases Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030

III. MARKET ANALYSIS

UNITED STATES

Lysosomal Storage Diseases Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
Table 14: USA Recent Past, Current & Future Analysis for Lysosomal Storage Diseases by Therapy - Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT) and Cystine Depleting Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 15: USA Historic Review for Lysosomal Storage Diseases by Therapy - Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT) and Cystine Depleting Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 16: USA 16-Year Perspective for Lysosomal Storage Diseases by Therapy - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT) and Cystine Depleting Agents for the Years 2014, 2024 & 2030

CANADA

Table 17: Canada Recent Past, Current & Future Analysis for Lysosomal Storage Diseases by Therapy - Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT) and Cystine Depleting Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 18: Canada Historic Review for Lysosomal Storage Diseases by Therapy - Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT) and Cystine Depleting Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 19: Canada 16-Year Perspective for Lysosomal Storage Diseases by Therapy - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT) and Cystine Depleting Agents for the Years 2014, 2024 & 2030

JAPAN

Lysosomal Storage Diseases Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
Table 20: Japan Recent Past, Current & Future Analysis for Lysosomal Storage Diseases by Therapy - Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT) and Cystine Depleting Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 21: Japan Historic Review for Lysosomal Storage Diseases by Therapy - Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT) and Cystine Depleting Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 22: Japan 16-Year Perspective for Lysosomal Storage Diseases by Therapy - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT) and Cystine Depleting Agents for the Years 2014, 2024 & 2030

CHINA

Lysosomal Storage Diseases Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
Table 23: China Recent Past, Current & Future Analysis for Lysosomal Storage Diseases by Therapy - Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT) and Cystine Depleting Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 24: China Historic Review for Lysosomal Storage Diseases by Therapy - Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT) and Cystine Depleting Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 25: China 16-Year Perspective for Lysosomal Storage Diseases by Therapy - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT) and Cystine Depleting Agents for the Years 2014, 2024 & 2030

EUROPE

Lysosomal Storage Diseases Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
Table 26: Europe Recent Past, Current & Future Analysis for Lysosomal Storage Diseases by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
Table 27: Europe Historic Review for Lysosomal Storage Diseases by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 28: Europe 16-Year Perspective for Lysosomal Storage Diseases by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
Table 29: Europe Recent Past, Current & Future Analysis for Lysosomal Storage Diseases by Therapy - Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT) and Cystine Depleting Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 30: Europe Historic Review for Lysosomal Storage Diseases by Therapy - Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT) and Cystine Depleting Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 31: Europe 16-Year Perspective for Lysosomal Storage Diseases by Therapy - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT) and Cystine Depleting Agents for the Years 2014, 2024 & 2030

FRANCE

Lysosomal Storage Diseases Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
Table 32: France Recent Past, Current & Future Analysis for Lysosomal Storage Diseases by Therapy - Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT) and Cystine Depleting Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 33: France Historic Review for Lysosomal Storage Diseases by Therapy - Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT) and Cystine Depleting Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 34: France 16-Year Perspective for Lysosomal Storage Diseases by Therapy - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT) and Cystine Depleting Agents for the Years 2014, 2024 & 2030

GERMANY

Lysosomal Storage Diseases Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
Table 35: Germany Recent Past, Current & Future Analysis for Lysosomal Storage Diseases by Therapy - Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT) and Cystine Depleting Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 36: Germany Historic Review for Lysosomal Storage Diseases by Therapy - Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT) and Cystine Depleting Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 37: Germany 16-Year Perspective for Lysosomal Storage Diseases by Therapy - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT) and Cystine Depleting Agents for the Years 2014, 2024 & 2030

ITALY

Table 38: Italy Recent Past, Current & Future Analysis for Lysosomal Storage Diseases by Therapy - Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT) and Cystine Depleting Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 39: Italy Historic Review for Lysosomal Storage Diseases by Therapy - Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT) and Cystine Depleting Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 40: Italy 16-Year Perspective for Lysosomal Storage Diseases by Therapy - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT) and Cystine Depleting Agents for the Years 2014, 2024 & 2030

UNITED KINGDOM

Lysosomal Storage Diseases Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
Table 41: UK Recent Past, Current & Future Analysis for Lysosomal Storage Diseases by Therapy - Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT) and Cystine Depleting Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 42: UK Historic Review for Lysosomal Storage Diseases by Therapy - Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT) and Cystine Depleting Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 43: UK 16-Year Perspective for Lysosomal Storage Diseases by Therapy - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT) and Cystine Depleting Agents for the Years 2014, 2024 & 2030

REST OF EUROPE

Table 44: Rest of Europe Recent Past, Current & Future Analysis for Lysosomal Storage Diseases by Therapy - Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT) and Cystine Depleting Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 45: Rest of Europe Historic Review for Lysosomal Storage Diseases by Therapy - Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT) and Cystine Depleting Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 46: Rest of Europe 16-Year Perspective for Lysosomal Storage Diseases by Therapy - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT) and Cystine Depleting Agents for the Years 2014, 2024 & 2030

ASIA-PACIFIC

Lysosomal Storage Diseases Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
Table 47: Asia-Pacific Recent Past, Current & Future Analysis for Lysosomal Storage Diseases by Therapy - Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT) and Cystine Depleting Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 48: Asia-Pacific Historic Review for Lysosomal Storage Diseases by Therapy - Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT) and Cystine Depleting Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 49: Asia-Pacific 16-Year Perspective for Lysosomal Storage Diseases by Therapy - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT) and Cystine Depleting Agents for the Years 2014, 2024 & 2030

REST OF WORLD

Table 50: Rest of World Recent Past, Current & Future Analysis for Lysosomal Storage Diseases by Therapy - Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT) and Cystine Depleting Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 51: Rest of World Historic Review for Lysosomal Storage Diseases by Therapy - Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT) and Cystine Depleting Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 52: Rest of World 16-Year Perspective for Lysosomal Storage Diseases by Therapy - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT) and Cystine Depleting Agents for the Years 2014, 2024 & 2030

IV. COMPETITION

Companies Mentioned

Alexion Pharmaceuticals, Inc.
BioMarin Pharmaceutical, Inc.
Horizon Therapeutics plc
Lacerta Therapeutics
Orphazyme ApS
Oxyrane
Sanofi Genzyme
Sanofi SA

Table Information

Report Attribute	Details
No. of Pages	193
Published	December 2024
Forecast Period	2023 - 2030
Estimated Market Value ( USD ) in 2023	$ 10.4 Billion
Forecasted Market Value ( USD ) by 2030	$ 15.2 Billion
Compound Annual Growth Rate	5.6%
Regions Covered	Global
No. of Companies Mentioned	8

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€4874EUR$4,950USD£4,039GBP
1 - 10 USER LICENSE PDF	The product is a PDF.	This is a 1-10 user license, allowing up to ten users have access to the product.	€9261EUR$9,405USD£7,674GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€14622EUR$14,850USD£12,117GBP

Key Insights:

Why You Should Buy This Report:

Key Questions Answered:

Report Features:

Select Competitors (Total 44 Featured):

Table of Contents

Companies Mentioned

Table Information

Related Topics

Related Reports

Lysosomal Disease Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F

Lysosomal Disease Treatment Global Market Report 2024

Lysosomal Storage Diseases Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Lysosomal Storage Diseases Market by Disease Type, Type of Therapy, End User - Global Forecast 2025-2030

Gaucher Disease Treatment Market - Forecasts from 2024 to 2029